Bill
Bill > HB1741
PA HB1741
PA HB1741Providing for prescribing and dispensing drugs approved by the United States Food and Drug Administration for off-label use to treat coronavirus infections causing respiratory syndrome-related illnesses.
summary
Introduced
07/30/2021
07/30/2021
In Committee
06/14/2022
06/14/2022
Crossed Over
Passed
Dead
11/30/2022
11/30/2022
Introduced Session
2021-2022 Regular Session
Bill Summary
Providing for prescribing and dispensing drugs approved by the United States Food and Drug Administration for off-label use to treat coronavirus infections causing respiratory-syndrome- related illnesses.
AI Summary
This bill provides for prescribing and dispensing drugs approved by the United States Food and Drug Administration (FDA) for off-label use to treat coronavirus infections causing respiratory-syndrome-related illnesses. It allows prescribers to prescribe and pharmacists to dispense such drugs with the informed consent of the patient, without requiring the patient to have a positive screening test or suspected exposure to coronavirus. The bill also protects prescribers and pharmacists from administrative or disciplinary actions by licensing boards or commissions, unless there is a showing of recklessness or gross negligence.
Committee Categories
Budget and Finance, Health and Social Services
Sponsors (18)
Dawn Keefer (R)*,
Aaron Bernstine (R),
Stephanie Borowicz (R),
Jim Cox (R),
Russ Diamond (R),
Mark Gillen (R),
Keith Greiner (R),
Joe Hamm (R),
Johnathan Hershey (R),
Mike Jones (R),
Rob Kauffman (R),
David Maloney (R),
Kathy Rapp (R),
David Rowe (R),
Frank Ryan (R),
Craig Staats (R),
Tim Twardzik (R),
Dave Zimmerman (R),
Last Action
Re-committed to APPROPRIATIONS (on 06/14/2022)
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...